Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 6/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.38 |
| ▸ | CDK2 | P24941 | 3/20 | 0.38 |
| ▸ | CCNK | O75909 | 2/20 | 0.38 |
| ▸ | CCND3 | P30281 | 2/20 | 0.38 |
| ▸ | CDK9 | P50750 | 2/20 | 0.38 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.38 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.37 |
| ▸ | AXL | P30530 | 2/20 | 0.36 |
| ▸ | INSR | P06213 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL375361 | 0.89 | CCNA2 (0.37) | ALKMAP4K1CCNA2CDK2CCNK | |
| SCHEMBL13849422 | 0.89 | CCNA2 (0.42) | ALKMAP4K1CCNA2CDK2CCNK | |
| SCHEMBL4100833 | 0.86 | MAP4K1 (0.41) | ALKMAP4K1CCNA2CDK2CCNK | |
| SCHEMBL375741 | 0.79 | LRRK2 (0.44) | ALKMAP4K1CCNA2CDK2CCNK | |
| SCHEMBL30942601 | 0.79 | CCNK (0.41) | ALKMAP4K1CCNA2CDK2CCNK | |
| SCHEMBL30141686 | 0.79 | CCNA2 (0.41) | ALKMAP4K1CCNA2CDK2CCNK | |
| SCHEMBL12311868 | 0.78 | LRRK2 (0.42) | ALKMAP4K1CCNA2CDK2CCNK | |
| SCHEMBL13849430 | 0.77 | CCNK (0.41) | ALKMAP4K1CCNA2CDK2CCNK | |
| SCHEMBL4105435 | 0.77 | ALK (0.68) | ALKCDK2INSRMAPK1MET | |
| SCHEMBL25014390 | 0.75 | CDK9 (0.40) | ALKMAP4K1CCNA2CDK2CCNK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| EP-1784392-A2 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006021454-A2 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | DPYD, TYMP, TYMS | ALK 2060/4885MAP4K1 2520/4885CCNA2 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.